MSNBA together with the active site differences between GLUT5 and GLUT1 highlighted by MSNBA inhibition can be exploited for the rational design of potent, specific inhibitors for GLUT5 that will aid in cancer or diabetes treatment. The gene discussed is SLC2A5; the disease is cancer.